Reciprocal regulation between natural killer cells and autoreactive T cells

Nature Reviews Immunology

Volumn 6, Issue 10, 2006, Pages 751-760

  Shi, Fu Dong ^a   Van Kaer, Luc ^b  

^a BARROW NEUROLOGICAL INSTITUTE   (United States)

^b VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; BETA INTERFERON; DACLIZUMAB; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY PK 136; PK 136; UNCLASSIFIED DRUG;

ADOPTIVE IMMUNOTHERAPY; AUTOIMMUNE DISEASE; AUTOIMMUNITY; CELL ACTIVATION; CELL POPULATION; DRUG EFFECT; HOMEOSTASIS; HUMAN; IMMUNE SYSTEM; INNATE IMMUNITY; MULTIPLE SCLEROSIS; NATURAL KILLER T CELL; NONHUMAN; PRIORITY JOURNAL; REVIEW; RHEUMATOID ARTHRITIS;

ANIMALS; AUTOIMMUNITY; CELL COMMUNICATION; CYTOTOXICITY, IMMUNOLOGIC; HUMANS; KILLER CELLS, NATURAL; LYMPHOCYTE ACTIVATION; MODELS, IMMUNOLOGICAL; T-LYMPHOCYTES;

EID: 33749027763     PISSN: 14741733     EISSN: None     Source Type: Journal    
DOI: 10.1038/nri1935     Document Type: Review

References (110)

1. Shi, F.-D., Ljunggren, H. G. & Sarvetnick, N. Innate immunity and autoimmunity: from self-protection to self-destruction. Trends Immunol. 22, 97-101 (2001).
2. McClain, M. T. et al. Early events in lupus humoral autoimmunity suggest initiation through molecular mimicry. Nature Med. 11, 85-89 (2005).
3. Fearon, D. T. & Locksley, R. M. The instructive role of innate immunity in the acquired immune response. Science 272, 50-53 (1996).
4. Pulendran, B. & Ahmed, R. Translating innate immunity into immunological memory: implications for vaccine development. Cell 124, 849-863 (2006).
5. King, C., Ilic, A., Koelsch, K. & Sarvetnick, N. Homeostatic expansion of T cells during immune insufficiency generates autoimmunity. Cell 117, 265-277 (2004).
6. Yokoyama, W. M. & Plougastel, B. F. Immune functions encoded by the natural killer gene complex. Nature Rev. Immunol. 3, 304-316 (2003).
7. Lanier, L. L. Natural killer cell receptor signaling. Curr. Opin. Immunol. 15, 308-314 (2003).
8. Karre, K., Ljunggren, H. G., Piontek, G. & Kiessling, R. Selective rejection of H-2-deficient lymphoma variants suggests alternative immune defense strategy. Nature 319, 675-678 (1986). This landmark paper shows that the amount of self MHC class I expression determines whether cells are targeted by NK cells, forming the basis of the 'missing-self' hypothesis.
9. Raulet, D. H. Interplay of natural killer cells and their receptors with the adaptive immune response. Nature Immunol. 5, 996-1002 (2004).
10. Yokoyama, W. M., Kim, S. & French, A. R. The dynamic life of natural killer cells. Annu. Rev. Immunol. 22, 405-429 (2004).
11. Lkawa, T., Kawamoto, H., Fujimoto, S. & Katsura, Y. Commitment of common T/natural killer (NK) progenitors to unipotent T and NK progenitors in the murine fetal thymus revealed by a single progenitor assay. J. Exp. Med. 190, 1617-1626 (1999).
12. Prlic, M., Blazar, B. R., Farrar, M. A. & Jameson, S. C. In vivo survival and homeostatic proliferation of natural killer cells. J. Exp. Med. 197, 967-976 (2003).
13. + cells. Blood 102, 127-135 (2003).
14. Glimcher, L. H., Townsend, M. J., Sullivan, B. M. & Lord, G. M. Recent developments in the transcriptional regulation of cytolytic effector cells. Nature Rev. Immunol. 4, 900-911 (2004).
15. Jiang, K. et al. Pivotal role of phosphoinositide-3 kinase in regulation of cytotoxicity in natural killer cells. Nature Immunol. 1, 419-425 (2000).
16. Jiang, K. et al. Syk regulation of phosphoinositide 3-kinase-dependent NK cell function. J. Immunol. 168, 3155-3164 (2002).
17. Biron, C. A., Nguyen, K. B., Pien, G. C., Cousens, L. P. & Salazar-Mather, T. P. Natural killer cells in antiviral defense: function and regulation by innate cytokines. Annu. Rev. Immunol. 17, 189-220 (1999).
18. Peritt, D. et al. Differentiation of human NK cells into NK1 and NK2 subsets. J. Immunol. 161, 5821-5824 (1998).
19. Loza, M. J. & Perussia, B. Final steps of natural killer cell maturation: a model for type 1-type 2 differentiation? Nature Immunol. 2, 917-924 (2001).
20. Katsumoto, T. et al. STAT6-dependent differentiation and production of IL-5 and IL-13 in murine NK2 cells. J. Immunol. 173, 4967-4975 (2004).
21. Takahashi, K. et al. Natural killer type 2 bias in remission of multiple sclerosis. J. Clin. Invest. 107, R23-R29 (2001).
22. Bolay, H. et al. α Interferon treatment in myasthenia gravis: effects on natural killer cell activity. J. Neuroimmunol. 82, 109-115 (1998).
23. Hartrich, L. et al. Dynamics of immune cell trafficking in interferon-β treated multiple sclerosis patients. J. Neuroimmunol. 139, 84-92 (2003).
24. Chambers, B. J., Salcedo, M. & Ljunggren, H. G. Triggering of natural killer cells by the costimulatory molecule CD80 (B7-1). Immunity 5, 311-317 (1996). This was the first paper to show that NK cells can target autologous DCs.
25. Wilson, J. L. et al. Targeting of human dendritic cells by autologous NK cells. J. Immunol. 163, 6365-6370 (1999).
26. Andrews, D. M., Scalzo, A. A., Yokoyama, W. M., Smyth, M. J. & Degli-Esposti, M. A. Functional interactions between dendritic cells and NK cells during viral infection. Nature Immunol. 4, 175-181 (2003).
27. Piccioli, D., Sbrana, S., Melandri, E. & Valiante, N. M. Contact-dependent stimulation and inhibition of dendritic cells by natural killer cells. J. Exp. Med. 195, 335-341 (2002).
28. Gerosa, F. et al. Reciprocal activating interaction between natural killer cells and dendritic cells. J. Exp. Med. 195, 327-333 (2002).
29. H1 and CTL responses: two-signal requirement for the induction of NK cell helper function. J. Immunol. 171, 2366-2373 (2003).
30. Carnaud, C. et al. Cross-talk between cells of the innate immune system: NKT cells rapidly activate NK cells. J. Immunol. 163, 4647-4650 (1999).
31. + B cells. J. Immunol. 167, 6132-6139 (2001).
32. Dowdell, K. C., Cua, D. J., Kirkman, E. & Stohlman, S. A. NK cells regulate CD4 responses prior to antigen encounter. J. Immunol. 171, 234-239 (2003).
33. Assarsson, E. et al. NK cells stimulate proliferation of T and NK cells through 2B4/CD48 interactions. J. Immunol. 173, 174-180 (2004).
34. + T cells via OX40-OX40 ligand interactions. J. Immunol. 173, 3716-3724 (2004).
35. Hanna, J. et al. Novel APC-like properties of human NK cells directly regulate T cell activation. J. Clin. Invest. 114, 1612-1623 (2004).
36. Trivedi, P. P., Roberts, P. C., Wolf, N. A. & Swanborg, R. H. NK cells inhibit T cell proliferation via p21-mediated cell cycle arrest. J. Immunol. 174, 4590-4597 (2005).
37. Gilmour, K. C. et al. Defective expression of the interleukin-2/ interleukin-15 receptor β subunit leads to a natural killer cell-deficient form of severe combined immunodeficiency. Blood 98, 877-879 (2001).
38. Biron, C. A., Byron, K. S. & Sullivan, J. L. Severe herpes virus infections in an adolescent without natural killer cells. N. Engl. J. Med. 320, 1731-1735 (1989).
39. Zimmer, J., Bausinger, H. & De la Salle, H. Autoimmunity mediated by innate immune effector cells. Trends Immunol. 22, 300-301 (2001).
40. Moins-Teisserenc, H. T. et al. Association of a syndrome resembling Wegener's granulomatosis with low surface expression of HLA class-I molecules. Lancet 354, 1598-1603 (1999).
41. Markel, G. et al. The mechanisms controlling NK cell autoreactivity in TAP2-deficient patients. Blood 103, 1770-1778 (2004).
42. Kerschensteiner, M., Stadelmann, C., Dechant, G., Wekerle, H. & Hohlfeld, R. Neurotrophic cross-talk between the nervous and immune systems: implications for neurological diseases. Ann. Neurol. 53, 292-304 (2003).
43. Hammarberg, H. et al. Neuroprotection by encephalomyelitis: rescue of mechanically injured neurons and neurotrophin production by CNS-infiltrating T and natural killer cells. J. Neurosci. 20, 5283-5291 (2000).
44. Backstrom, E. et al. Natural killer cell-mediated lysis of dorsal root ganglia neurons via RAE1/NKG2D interactions. Eur. J. Immunol. 33, 92-100 (2003).
45. Morse, R. H., Seguin, R., McCrea, E. L. & Antel, J. P. NK cell-mediated lysis of autologous human oligodendrocytes. J. Neuroimmunol. 116, 107-115 (2001).
46. Antel, J. P., McCrea, E., Ladiwala, U., Qin, Y. F. & Becher, B. Non-MHC-restricted cell-mediated lysis of human oligodendrocytes in vitro: relation with CD56 expression. J. Immunol. 160, 1606-1611 (1998).
47. Trinchieri, G. Biology of natural killer cells. Adv. Immunol. 47, 187-376 (1989).
48. Shibatomi, K. et al. A novel role for interleukin-18 in human natural killer cell death: high serum levels and low natural killer cell numbers in patients with systemic autoimmune diseases. Arthritis Rheum. 44, 884-892 (2001).
49. Grom, A. A. et al. Natural killer cell dysfunction in patients with systemic-onset juvenile rheumatoid arthritis and macrophage activation syndrome. J. Pediatr. 142, 292-296 (2003).
50. + T cells in the thymus of patients with autoimmune myasthenia gravis. Blood 105, 735-741 (2005).
51. + regulatory T cells in patients with multiple sclerosis. J. Exp. Med. 199, 971-979 (2004).
52. Regs and NKT cells: regulators regulating regulators. Trends Immunol. 27, 322-327 (2006).
53. Ehl, S. et al. A comparison of efficacy and specificity of three NK depleting antibodies. J. Immunol. Methods 199, 149-153 (1996).
54. Ortaldo, J. R. & Young, H. A. Expression of IFN-γ upon triggering of activating Ly49D NK receptors in vitro and in vivo: costimulation with IL-12 or IL-18 overrides inhibitory receptors. J. Immunol. 170, 1763-1769 (2003).
55. Suzuki, H., Duncan, G. S., Takimoto, H. & Mak, T. W. Abnormal development of intestinal intraepithelial lymphocytes and peripheral natural killer cells in mice lacking the IL-2 receptor β chain. J. Exp. Med. 185, 499-505 (1997).
56. Fehniger, T. A. & Caligiuri, M. A. Interleukin 15: biology and relevance to human disease. Blood 97, 14-32 (2001).
57. Lodolce, J. P. et al. IL-15 receptor maintains lymphoid homeostasis by supporting lymphocyte homing and proliferation. Immunity 9, 669-676 (1998).
58. Kennedy, M. K. et al. Reversible defects in natural killer and memory CD8 T cell lineages in interleukin 15-deficient mice. J. Exp. Med. 191, 771-780 (2000).
59. H1 response in IL-18-deficient mice. Immunity 8, 383-390 (1998).
60. Adachi, O. et al. Targeted disruption of the MyD88 gene results in loss of IL-1- and IL-18-mediated function. Immunity 9, 143-150 (1998).
61. Kim, S., Iizuka, K., Aguila, H. L., Weissman, I. L. & Yokoyama, W. M. In vivo natural killer cell activities revealed by natural killer cell-deficient mice. Proc. Natl Acad. Sci. USA 97, 2731-2736 (2000).
62. Townsend, M. J. et al. T-bet regulates the terminal maturation and homeostasis of NK and Vα14i NKT cells. Immunity 20, 477-494 (2004).
63. Flodstrom, M., Shi, F.-D., Sarvetnick, N. & Ljunggren, H. G. The natural killer cell - friend or foe in autoimmune disease? Scand. J. Immunol. 55, 432-441 (2002).
64. French, A. R. & Yokoyama, W. M. Natural killer cells and autoimmunity. Arthritis Res. Ther. 6, 8-14 (2004).
65. Johansson, S., Berg, L., Hall, H. & Hoglund, P. NK cells: elusive players in autoimmunity. Trends Immunol. 26, 613-618 (2005).
66. Maruyama, T. et al. Anti-asialo GM1 antibody suppression of cyclophosphamide-induced diabetes in NOD mice. Diabetes Res. 17, 37-41 (1991).
67. + T cells in a transfer model of colitis. J. Immunol. 161, 3256-3261 (1998).
68. + cells in experimental Staphylococcus aureus arthritis. Clin. Exp. Immunol. 117, 63-69 (1999).
69. Korsgren, M. et al. Natural killer cells determine development of allergen-induced eosinophilic airway inflammation in mice. J. Exp. Med. 189, 553-562 (1999).
70. Matsumoto, Y. et al. Role of natural killer cells and TCR γδ T cells in acute autoimmune encephalomyelitis. Eur. J. Immunol. 28, 1681-1688 (1998).
71. Zhang, B., Yamamura, T., Kondo, T., Fujiwara, M. & Tabira, T. Regulation of experimental autoimmune encephalomyelitis by natural killer (NK) cells. J. Exp. Med. 186, 1677-1687 (1997).
72. Shi, F.-D. et al. Natural killer cells determine the outcome of B cell-mediated autoimmunity. Nature Immunol. 1, 245-251 (2000). This was the first study to indicate that NK cells have different roles in the initiation and the progression of autoimmune disease.
73. Johansson, S. E., Hall, H., Bjorklund, J. & Hoglund, P. Broadly impaired NK cell function in non-obese diabetic mice is partially restored by NK cell activation in vivo and by IL-12/IL-18 in vitro. Int. Immunol. 16, 1-11 (2004).
74. Ogasawara, K. et al. NKG2D blockade prevents autoimmune diabetes in NOD mice. Immunity 20, 757-767 (2004).
75. Poirot, L., Benoist, C. & Mathis, D. Natural killer cells distinguish innocuous and destructive forms of pancreatic islet autoimmunity. Proc. Natl Acad. Sci. USA 101, 8102-8107 (2004).
76. Flodstrom, M. et al. Target cell defense prevents the development of diabetes after viral infection. Nature Immunol. 3, 373-382 (2002).
77. Lee, I. F., Qin, H., Trudeau, J., Dutz, J. & Tan, R. Regulation of autoimmune diabetes by complete Freund's adjuvant is mediated by NK cells. J. Immunol. 172, 937-942 (2004).
78. Paya, C. V., Patick, A. K., Leibson, P. J. & Rodriguez, M. Role of natural killer cells as immune effectors in encephalitis and demyelination induced by Theiler's virus. J. Immunol. 143, 95-102 (1989).
79. Xu, W., Fazekas, G., Hara, H. & Tabira, T. Mechanism of natural killer (NK) cell regulatory role in experimental autoimmune encephalomyelitis. J. Neuroimmunol. 163, 24-30 (2005).
80. Smeltz, R. B., Wolf, N. A. & Swanborg, R. H. Inhibition of autoimmune T cell responses in the DA rat by bone marrow-derived NK cells in vitro: implications for autoimmunity. J. Immunol. 163, 1390-1397 (1999).
81. Shi, F.-D., Takeda, K., Akira, S., Sarvetnick, N. & Ljunggren, H. G. IL-18 directs autoreactive T cells and promotes autodestruction in the central nervous system via induction of IFN-γ by NK cells. J. Immunol. 165, 3099-3104 (2000). References 66-81 show that NK cells have an important role in several experimental autoimmune diseases. These studies also provide important insights into the mechanisms that are involved in these diseases.
82. Bettelli, E. et al. Loss of T-bet, but not STAT1, prevents the development of experimental autoimmune encephalomyelitis. J. Exp. Med. 200, 79-87 (2004).
83. Takeda, K. & Dennert, G. The development of autoimmunity in C57BL/6 lpr mice correlates with the disappearance of natural killer type 1-positive cells: evidence for their suppressive action on bone marrow stem cell proliferation, B cell immunoglobulin secretion, and autoimmune symptoms. J. Exp. Med. 177, 155-164 (1993).
84. Mendiratta, S. K. et al. CD1d1 mutant mice are deficient in natural T cells that promptly produce IL-4. Immunity 6, 469-477 (1997).
85. + T cells is associated with activation and subsequent cell death or memory during influenza virus infection. Eur. J. Immunol. 31, 1523-1530 (2001).
86. + T cells upon NKR-P1 cross-linking. J. Exp. Med. 183, 2391-2396 (1996).
87. O'Garra, A. Cytokines induce the development of functionally heterogeneous T helper cell subsets. Immunity 8, 275-283 (1998).
88. H2 responses: a key role for the 'natural' immune response? Immunol. Today 13, 379-381 (1992).
89. H1 priming. Nature Immunol. 5, 1260-1265 (2004).
90. Laouar, Y., Sutterwala, F. S., Gorelik, L. & Flavell, R. A. Transforming growth factor-β controls T helper type 1 cell development through regulation of natural killer cell interferon-γ. Nature Immunol. 6, 600-607 (2005). References 89 and 90 provide insights into the mechanism of regulation of autoreactive T cells by cytokines produced by NK cells.
91. Zitvogel, L., Terme, M., Borg, C. & Trinchieri, G. Dendritic cell-NK cell cross-talk: regulation and physiopathology. Curr. Top. Microbiol. Immunol. 298, 157-174 (2006).
92. Banchereau, J., Pascual, V. & Palucka, A. K. Autoimmunity through cytokine-induced dendritic cell activation. Immunity 20, 539-550 (2004).
93. Fernandez, N. C. et al. Dendritic cells directly trigger NK cell functions: cross-talk relevant in innate anti-tumor immune response in vivo. Nature Med. 5, 405-411 (1999). This study shows the crosstalk that occurs between NK cells and DCs under pathophysiological conditions.
94. Charo, I. F. & Ransohoff, R. M. The many roles of chemokines and chemokine receptors in inflammation. N. Engl. J. Med. 354, 610-621 (2006).
95. Salazar-Mather, T. P., Hamilton, T. A. & Biron, C. A. A chemokine-to-cytokine-to-chemokine cascade critical in antiviral defense. J. Clin. Invest. 105, 985-993 (2000).
96. + NK and NK-T peripheral blood lymphocytes identified by chemokine receptor expression repertoire. J. Immunol. 166, 6477-6482 (2001).
97. 3CR1 reveals a role for fractalkine in cardiac allograft rejection. J. Clin. Invest. 108, 679-688 (2001).
98. 3CL1 as the main chemoattractant for NK-cell homing to the CNS, a process that modulates the magnitude of EAE.
99. hi NK cells.
100. Liu, R. L. et al. Autoreactive T cells mediate NK cell degeneration in autoimmune disease. J. Immunol. 176, 5247-5254 (2006). This study shows that autoreactive T cells contribute to NK-cell degeneration and that NK-cell degeneration might have evolved to allow the immune system to control excessive autoimmunity.
101. Waldmann T. A., Dubois, S. & Tagaya, Y. Contrasting roles of IL-2 and IL-15 in the life and death of lymphocytes: implications for immunotherapy. Immunity 14, 105-110 (2001).
102. Koka, R. et al. Interleukin (IL)-15Rα-deficient natural killer cells survive in normal but not IL-15Rα-deficient mice. J. Exp. Med. 197, 977-984 (2003).
103. Cooper, M. A. et al. In vivo evidence for a dependence on interleukin 15 for survival of natural killer cells. Blood 100, 3633-3638 (2002).
104. Leonard, W. J. & Spolski, R. Interleukin-21: a modulator of lymphoid proliferation, apoptosis and differentiation. Nature Rev. Immunol. 5, 688-698 (2005).
105. Kasaian, M. T. et al. IL-21 limits NK cell responses and promotes antigen-specific T cell activation: a mediator of the transition from innate to adaptive immunity. Immunity 16, 559-569 (2002).
106. Vollmer, T. L. et al. Differential effects of IL-21 during initiation and progression of autoimmunity against neuroantigen. J. Immunol. 174, 2696-2701 (2005). References 105 and 106 show that the effect of IL-21 on NK-cell function depends on the status of NK-cell activation.
107. Vollmer, T. L. et al. Oral simvastatin treatment in relapsing-remitting multiple sclerosis. Lancet 363, 1607-1608 (2004).
108. Van Kaer, L. α-Galactosylceramide therapy for autoimmune diseases: prospects and obstacles. Nature Rev. Immunol. 5, 31-42 (2005).
109. bright natural killer cells mediate immunomodulatory effects of IL-2R-targeted therapy (daclizumab) in multiple sclerosis. Proc. Natl Acad. Sci. USA 103, 5941-5946 (2006).
110. bright regulatory NK cells in patients with active uveitis. J. Immunol. 174, 5187-5191 (2005).